CORAL XT - Open-label Extension Trial of the CORAL Trial
Status:
Completed
Trial end date:
2016-05-03
Target enrollment:
Participant gender:
Summary
The purpose of this trial was to find out how well cebranopadol is tolerated and how often,
and which, adverse reactions occur when it is taken every day for a longer period of time. In
addition, information was collected how cebranopadol affects pain and well-being in patients
suffering from cancer-related pain.